These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15466216)

  • 1. Symposium on androgen action in prostate cancer.
    Tindall D; Horne FM; Hruszkewycz A; Mohla S; Shuman M; Wang Z; Kantoff P
    Cancer Res; 2004 Oct; 64(19):7178-80. PubMed ID: 15466216
    [No Abstract]   [Full Text] [Related]  

  • 2. Id-1 expression in androgen-dependent prostate cancer is negatively regulated by androgen through androgen receptor.
    Xu B; Sun Y; Tang G; Xu C; Wang L; Zhang Y; Ji J
    Cancer Lett; 2009 Jun; 278(2):220-229. PubMed ID: 19201527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving toward personalized medicine in castration-resistant prostate cancer.
    Van Allen EM; Pomerantz M
    Urol Clin North Am; 2012 Nov; 39(4):483-90. PubMed ID: 23084525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 6. The androgen receptor for the radiation oncologist.
    Quero L; Rozet F; Beuzeboc P; Hennequin C
    Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The androgen receptor and mechanisms for androgen independence in prostate cancer.
    Javidan J; Deitch AD; Shi XB; de Vere White RW
    Cancer Invest; 2005; 23(6):520-8. PubMed ID: 16203660
    [No Abstract]   [Full Text] [Related]  

  • 8. Uses and limitations of hormone, receptor and enzyme assays in prostate cancer.
    Martin PM; Le Goff JM; Brisset JM; Ojasoo T; Husson JM; Raynaud JP
    Prog Clin Biol Res; 1987; 243A():111-40. PubMed ID: 3309969
    [No Abstract]   [Full Text] [Related]  

  • 9. The androgen receptor: a potential target for therapy of prostate cancer.
    Santos AF; Huang H; Tindall DJ
    Steroids; 2004 Feb; 69(2):79-85. PubMed ID: 15013685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 11. How should we understand the term androgen deprivation therapy?
    Drewa T; Soloway MS
    Eur Urol; 2012 Apr; 61(4):856. PubMed ID: 22266269
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular and cellular biology of the prostate: is it clinically relevant?
    Habib FK; Grant ES
    Br J Urol; 1996 Oct; 78(4):546-51. PubMed ID: 8963637
    [No Abstract]   [Full Text] [Related]  

  • 13. The testosterone conundrum: The putative relationship between testosterone levels and prostate cancer.
    Loughlin KR
    Urol Oncol; 2016 Nov; 34(11):482.e1-482.e4. PubMed ID: 27423822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal implications in the development and treatment of prostate cancer.
    Ip C; Hall SJ
    Endocrinol Metab Clin North Am; 2007 Jun; 36(2):421-34. PubMed ID: 17543727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Cancer: Current Issues, New Approaches. Proceedings of an international congress. London, England, October 19-21, 1995.
    Eur Urol; 1996; 29 Suppl 2():1-135. PubMed ID: 8717451
    [No Abstract]   [Full Text] [Related]  

  • 16. Hormone-dependence of prostatic cancer and principles of androgen deprivation.
    Neumann F
    Arch Ital Urol Androl; 1993 Dec; 65(6):633-45. PubMed ID: 8312946
    [No Abstract]   [Full Text] [Related]  

  • 17. [The mechanism of hormone-independent recurrence of prostate cancer].
    Fukabori Y
    Nihon Rinsho; 2000 Jul; 58 Suppl():45-52. PubMed ID: 11022683
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular profiles of finasteride effects on prostate carcinogenesis.
    Li J; Kim J
    Cancer Prev Res (Phila); 2009 Jun; 2(6):518-24. PubMed ID: 19491289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Fritz H. Schröder. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008;53:1129-37.
    Drewa T
    Eur Urol; 2009 Jan; 55(1):e6-7; author reply e8-9. PubMed ID: 18603349
    [No Abstract]   [Full Text] [Related]  

  • 20. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.
    Gregory CW; He B; Johnson RT; Ford OH; Mohler JL; French FS; Wilson EM
    Cancer Res; 2001 Jun; 61(11):4315-9. PubMed ID: 11389051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.